Startup | May 09, 2022
InxMed raises US $ 15 million in Series B+ financing
The plan is to advance innovative therapies to drug-resistant cancers
The plan is to advance innovative therapies to drug-resistant cancers
An estimated 21 million American women experience BV
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
The company has 271 cumulative ANDA filings with USFDA of which 243 ANDAs have been approved and 28 are pending approval
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
The company has developed the API in house at its R&D center in Hyderabad
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
Clindamycin Phosphate Foam, 1% is the generic version of Evoclin Foam, 1%
Zydus’ Sitagliptin base contains the active moiety Sitagliptin in a different form than used in the branded reference product, Januvia (Sitagliptin Phosphate)
Researchers from IIT Bombay and QIMR Berghofer Medical Research Institute, Australia have developed this method, based on the Agilent Cary 630 FTIR Spectrometer
Subscribe To Our Newsletter & Stay Updated
